Everest Medicines

Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China's NMPA, Driving Continued Commercial Momentum

2 Oct 2026

ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines' CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment Option

21 Sept 2026

Everest Medicines Strengthens Its Cardiovascular Portfolio with CARDAMYST(R) Approved for the Conversion of Acute Symptomatic Episodes of PSVT to Sinus Rhythm in Adults in China

3 Sept 2026

Micot Pharma Reports Positive Operating Cash Flow and Advances Late-Stage Pipeline in 1H 2026

31 Aug 2026

Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum

19 Aug 2026

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

8 Jul 2026

Everest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a Potential New Treatment Option for Hypercholesterolemia in China

26 Jun 2026

Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules, further enhancing patient access to the medication

24 Jun 2026

Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia

16 Jun 2026

Everest Medicines Secures Exclusive License for Sumecigrel in Asia-Pacific, Expanding Its Cardiovascular Product Portfolio

9 Jun 2026

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China, Strengthen Presence in Ophthalmology

8 Jun 2026

Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin(R) in the Asia-Pacific Market

4 Jun 2026